McCamish Mark Anthony
Known title: DirectorCIK: 0001390798
Associated companies
Transaction History
| RFL | ▲ Buy | Grant | 27,655 | $50K | 1/5/2024 | View on chart |
| RFL | ▲ Buy | Grant | 27,174 | $50K | 1/5/2023 | View on chart |
| RFL | ▲ Buy | Grant | 5,412 | $29K | 1/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Rafael Holdings stock drops after Phase 3 trial misses goal
Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.
Rafael Holdings stock drops after Phase 3 trial misses goal. Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.